Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.

AAV2-GAD gene therapy for advanced Parkinson’s disease: a double-blind, sham-surgery controlled, randomised trial

Abstract

Background Gene transfer of glutamic acid decarboxylase (GAD) and other methods that modulate production of GABA in the subthalamic nucleus improve basal ganglia function in parkinsonism in animal models. We aimed to assess the effect of bilateral delivery of AAV2-GAD in the subthalamic nucleus compared with sham surgery in patients with advanced Parkinson's disease.Methods Patients aged 30-75 years who had progressive levodopa-responsive Parkinson's disease and an overnight off-medication unified Parkinson's disease rating scale (UPDRS) motor score of 25 or more were enrolled into this double-blind, phase 2, randomised controlled trial, which took place at seven centres in the USA between Nov 17, 2008, and May 11, 2010. Infusion failure or catheter tip location beyond a predefined target zone led to exclusion of patients before unmasking for the efficacy analysis. The primary outcome measure was the 6-month change from baseline in double-blind assessment of off-medication UPDRS motor scores. This trial is registered with ClinicalTrials.gov, NCT00643890.Findings Of 66 patients assessed for eligibility, 23 were randomly assigned to sham surgery and 22 to AAV2-GAD infusions; of those, 21 and 16, respectively, were analysed. At the 6-month endpoint, UPDRS score for the AAV2-GAD group decreased by 8·1 points (SD 1·7, 23·1%; p<0·0001) and by 4·7 points in the sham group (1·5, 12·7%; p=0·003). The AAV2-GAD group showed a significantly greater improvement from baseline in UPDRS scores compared with the sham group over the 6-month course of the study (RMANOVA, p=0·04). One serious adverse event occurred within 6 months of surgery; this case of bowel obstruction occurred in the AAV2-GAD group, was not attributed to treatment or the surgical procedure, and fully resolved. Other adverse events were mild or moderate, likely related to surgery and resolved; the most common were headache (seven patients in the AAV2-GAD group vs two in the sham group) and nausea (six vs two).Interpretation The efficacy and safety of bilateral infusion of AAV2-GAD in the subthalamic nucleus supports its further development for Parkinson's disease and shows the promise for gene therapy for neurological disorders.Funding Neurologix.

Overview

Integrity signals

Registry

Crossref · 10.1016/s1474-4422(11)70039-4

Cites

38 of 38 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 38 references

Cited by

See all 681

Metadata

Authors
LeWitt, P. A., Rezai, A. R., Leehey, M. A., Ojemann, S. G., Flaherty, A. W., Eskandar, E. N., Kostyk, S. K., Thomas, K., Sarkar, A., Siddiqui, M. S., Tatter, S. B., Schwalb, J. M., Poston, K. L., Henderson, J. M., Kurlan, R. M., Richard, I. H., Van Meter, L., Sapan, C. V., During, M. J., Kaplitt, M. G., & Feigin, A.
Affiliations
  • Wayne State University (US)
  • The Ohio State University (US)
  • University of Colorado Anschutz (US)
  • Massachusetts General Hospital (US)
  • Wake Forest University Health Sciences (US)
  • Henry Ford Health (US)
  • Stanford Medicine (US)
  • University of Rochester Medicine (US)
  • Weill Cornell Medicine (US)
  • Northwell Health (US)
Corresponding author
Feigin, Andrew
Venue
The Lancet Neurology
Publisher
Elsevier BV
Published
2011-04
Volume
10
Issue
4
Pages
309-319
ISSN
1474-4422 (ISSN-L)
OpenAlex
W2014850190
Cited by
681
References
38
Citations by year
2026: 19 · 2025: 27 · 2024: 34 · 2023: 26 · 2022: 20 · 2021: 55 · 2020: 45 · 2019: 37 · 2018: 40 · 2017: 39 · 2016: 49 · 2015: 56 · 2014: 58 · 2013: 70 · 2012: 60
FWCI
47.04
Type
journal article
Language
en
Open access
closed
Licence
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
  • www.elsevier.com/legal/tdmrep-license (tdm)
Locations
  • The Lancet Neurology (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Dana Foundation
  • Thomas Hartman Foundation for Parkinson’s Research
  • Merck
  • UCB
  • Novartis
  • Rockefeller University
  • Teva Pharmaceutical Industries
  • Boehringer Ingelheim
  • International Parkinson and Movement Disorder Society
  • U.S. Department of Defense
  • Schering-Plough
  • Ipsen
  • National Institute of Neurological Disorders and Stroke
  • Weill Cornell Medical College
  • Michael J. Fox Foundation for Parkinson&apos;s Research
  • Allergan
  • Huntington&apos;s Disease Society of America
  • Parkinson Study Group
  • Alnylam Pharmaceuticals
  • ACADIA Pharmaceuticals
  • National Institutes of Health
  • Ohio State University
  • H. Lundbeck A/S
Topics
  • Health Sciences › Medicine › Clinical Neurology › Deep Brain Stimulation and Movement Disorders
  • Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
Keywords
gene therapy, glutamic acid decarboxylase, subthalamic nucleus, basal ganglia, GABA, levodopa-responsive parkinsonism, UPDRS motor score, adverse events, intestinal obstruction, surgical safety, advanced Parkinson's disease
MeSH terms
Adult, Aged, Double-Blind Method, Female, Glutamate Decarboxylase, Humans, Male, Middle Aged, Parkinson Disease, Genetic Therapy, Treatment Outcome, Gene Transfer Techniques, Subthalamic Nucleus

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: AAV2-GAD gene therapy for advanced Parkinson’s disease: a double-blind, sham-surgery controlled, randomised trial. https://app.cochat.ai/papers/10.1016/s1474-4422(11)70039-4
The paper
LeWitt, P. A., Rezai, A. R., Leehey, M. A., Ojemann, S. G., Flaherty, A. W., Eskandar, E. N., Kostyk, S. K., Thomas, K., Sarkar, A., Siddiqui, M. S., Tatter, S. B., Schwalb, J. M., Poston, K. L., Henderson, J. M., Kurlan, R. M., Richard, I. H., Van Meter, L., Sapan, C. V., During, M. J., . . . Feigin, A. (2011). AAV2-GAD gene therapy for advanced Parkinson’s disease: a double-blind, sham-surgery controlled, randomised trial. The Lancet Neurology. https://doi.org/10.1016/s1474-4422(11)70039-4

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.